Risk-Benefit Analysis and Personalized Treatment in MS

For many patients with MS, current disease-modifying therapies (DMTs) can provide control of disease activity especially when more aggressive treatment is initiated early in the disease course. The CE-certified supplement, Risk-Benefit Analysis and Personalized Treatment in Multiple Sclerosis: Basing Treatment Goals on the Latest Evidence, provides clinicians with the most up-to-date evidence on current and emerging MS therapies and treatment goals, as well as treatment strategies to achieve those goals.


Patricia K. Coyle, MD, FAAN, FANA

Professor and Vice Chair (Clinical Affairs) Department of Neurology

Director, MS Comprehensive Care Center

Stony Brook University Medical Center

Stony Brook, NY



Clyde E. Markowitz, MD

Director, MS Center

Associate Professor of Neurology

Perelman School of Medicine

University of Pennsylvania

Philadelphia, PA

Jointly provided by Potomac Center for Medical Education, the Consortium of Multiple Sclerosis Centers, and Rockpointe.

This supplement is supported by educational grants from Biogen, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.